ProfileGDS5678 / 1456039_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 83% 81% 78% 81% 84% 83% 83% 81% 82% 82% 81% 82% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.9314282
GSM967853U87-EV human glioblastoma xenograft - Control 26.1339183
GSM967854U87-EV human glioblastoma xenograft - Control 35.8700281
GSM967855U87-EV human glioblastoma xenograft - Control 45.5688878
GSM967856U87-EV human glioblastoma xenograft - Control 55.8968981
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.0534284
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.9092283
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.020583
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.8450381
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.948582
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.918482
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.8411281
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.9141682
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.9011182